{"id":54917,"date":"2024-04-24T07:00:00","date_gmt":"2024-04-24T05:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2024\/"},"modified":"2024-07-23T11:51:41","modified_gmt":"2024-07-23T09:51:41","slug":"ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2024","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2024\/","title":{"rendered":"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l’exercice 2024"},"content":{"rendered":"

PARIS, FRANCE, 24 avril 2024 <\/strong>– Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de sp\u00e9cialit\u00e9, publie aujourd\u2019hui son chiffre d\u2019affaires pour le premier trimestre 2024.<\/p>\n\n\n\n\n\n\n\n\n
\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/td>\n

Q1 2024<\/strong>\u00a0<\/td>\nQ1 2023\u00a0<\/strong><\/td>\n% change<\/strong>\u00a0<\/td>\n<\/tr>\n
\u20acm<\/strong>\u00a0<\/td>\n\u20acm<\/strong>\u00a0<\/td>\nR\u00e9alis\u00e9<\/strong>\u00a0<\/td>\nTTC<\/strong>1<\/strong><\/sup><\/td>\n<\/tr>\n
Plateforme de croissance2<\/sup>\u00a0<\/td>\n509,7<\/td>\n452,0<\/td>\n12,8%<\/td>\n16,2%<\/td>\n<\/tr>\n
Nouveaux m\u00e9dicaments3<\/sup>\u00a0<\/td>\n45,5<\/td>\n14,3<\/td>\nn\/a<\/td>\nn\/a<\/td>\n<\/tr>\n
Somatuline\u00ae<\/em><\/sup>\u00a0<\/td>\n257,8<\/td>\n263,2<\/td>\n-2,0%<\/td>\n-1,3%<\/td>\n<\/tr>\n
Autres\u00a0<\/td>\n9,5<\/td>\n12,4<\/td>\n-23,8%<\/td>\n-20,5%<\/td>\n<\/tr>\n
Chiffre d\u2019affaires Groupe<\/strong>\u00a0<\/td>\n822,4<\/strong><\/td>\n741,9<\/strong><\/td>\n10.9%<\/strong><\/td>\n13.3%<\/strong><\/td>\n<\/tr>\n<\/table>\n

Faits marquants<\/strong><\/p>\n